UI-102 treatment for advanced cancer
Part of Cancer clinical trials.
This early-stage trial tests a new drug called UI-102 in people with advanced cancer. Researchers want to see if it is safe and whether it can help shrink tumors in patients who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer confirmed by a biopsy or tissue sample
- Your cancer has measurable tumors that can be tracked on imaging
- You are in good enough health to handle treatment (ECOG score 0–1, meaning you can do most daily activities)
- You have already received standard cancer treatments
- You have a recent tumor tissue sample available for testing
- If you can have children, you agree to use reliable birth control during the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
This trial tests a new drug (IM-1021) for people with advanced cancers like lymphoma or solid tumors who have run out of standard options. The drug targets a protein called ROR1, which is found on some cancer cells, and may help shrink tumors or slow their growth.
This trial tests a new drug called SC-102 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if SC-102 is safe and how well it works.
This trial tests a new drug, KIVU-107, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this drug is safe and helps shrink or control the cancer.
This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.
This trial studies a new drug called BB102 that targets a specific protein (FGF19/FGFR4) found on some cancer cells. It is for people with advanced solid tumors, especially liver cancer, who have run out of standard treatment options. The goal is to see if the drug is safe and helps shrink or control the cancer.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.